Document:

Exhibit 10.32

 

ASSIGNMENT OF INVENTION AND
PATENT APPLICATION

Whereas I, Christine Ichim,
a citizen of the Canada residing in Spring Valley, CA herein referred to as ASSIGNOR, have invented new and useful innovations
described in METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY INHIBITION OF NR2F6, the specification of which was filed
on December 15, 2014 as U.S. Non-Provisional Patent Application No 14/571,262, herein referred to as the Invention

And Whereas, Regen BioPharma,
Inc., with its principal place of business at 4700 Spring St., Suite 304, La Mesa, CA 91942 herein referred to as ASSIGNEE, desires
to acquire the entire right, title, and interest in and to the said Invention,

Now therefore, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby acknowledges that they have
sold, assigned, transferred, and set over, and by these presents do hereby sell, assign, and transfer, and set over unto ASSIGNEE
and its successors and assigns, 100% of the following:

(A) ASSIGNOR’S right,
title and interest in and to the Invention entitled in METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY INHIBITION OF NR2F6,
US Non- Provisional Patent Application No. 14/571,262 filed December 15, 2014,

(B) any patent or reissues that
claim priority to U.S. Non-Provisional Application No 14/571,262; and

(C) any continuations, continuations-in-part,
substitutes, or divisionals that claim priority to US Non-Provisional Application No. 14/571,262.

ASSIGNOR authorizes and requests
the Commissioner for Patents to issue any resulting patent(s) as follows: 0% to ASSIGNOR and 100% to ASSIGNEE.

ASSIGNOR hereby further sells,
assigns, transfers and sets over unto ASSIGNEE, 100% of ASSIGNOR’S entire right, title, and interest in and to said invention
in the United States and every country foreign to the United States. ASSIGNOR agrees to execute all papers, give any required testimony,
and perform other lawful acts, at ASSIGNEE’S expense, as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE’S
interest in any resulting patent of the United States and countries foreign thereto, and to acquire, hold, enforce, convey, and
uphold the validity of said patent and reissues and extensions thereof, and ASSIGNEE’S interest therein. 

In testimony whereof ASSIGNOR
intending to be legally bound hereunto affix his signature.

ASSIGNOR 

	/s/ Christine Ichim	December 16, 2014
	(Christine Ichim)	(Date)Exhibit 10.33

 

ASSIGNMENT OF INVENTION AND
PATENT APPLICATION

PARTIES

Whereas, I, Christine Ichim
(“ASSIGNOR”), a natural person and residing at 12685 Campo Road, Spring Valley CA 91978 desire to assign any and all
ownership interest in the inventions described in U.S. Patent Application Serial No. 13/652,395, filed on October 15th, 2012, “Modulation
of NR2F6 and methods and uses thereof” known as the “Invention”.

Whereas, Regen Biopharma, Inc.
(“ASSIGNEE”), a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942 desires to
acquire the entire right, title, and interest in and to the Invention.

REPRESENTATION
OF ASSIGNOR

ASSIGNOR represents that she
currently holds sole right, title, and interest in United States Patent Application 13/652,395.

ASSIGNMENT

Now therefore, for the Consideration
listed below, ASSIGNOR hereby acknowledges that they have sold, assigned, transferred, and set over, and by these presents do hereby
sell, assign, and transfer, and set over unto ASSIGNEE and its successors and assigns, the entire 100% of the following:

(A) any of ASSIGNOR’S
right, title and interest in and to the Invention described in Patent Application Serial No. 13/652,395;

(B) any patent or reissues of
any patent that may be granted thereon;

(C) ASSIGNOR authorizes and
requests the Commissioner for Patents to issue any resulting patent(s) as follows: 0% to ASSIGNOR and 100% to ASSIGNEE; and

(D) any applications which are
non-provisionals, continuations, continuations-in-part, substitutes, or divisions of Patent Application Serial No. 13/652,395.

CONSIDERATION

As Consideration, ASSIGNOR shall
be issued One Hundred Thousand Common Shares of the ASSIGNEE for the rights to Application Serial No. 13/652,395,

ASSIGNOR DUTIES AND RIGHTS

ASSIGNOR hereby further sells,
assigns, transfers and sets over unto ASSIGNEE, 100% of ASSIGNOR’S entire right, title, and interest in and to said Invention
in each and every country foreign to the United States; and ASSIGNOR further conveys to ASSIGNEE the above percentage of all priority
rights resulting from the above-identified application for United States patent.

ASSIGNOR agrees to execute all
papers, give any required testimony, and perform other lawful acts as ASSIGNEE may require to enable ASSIGNEE to perfect ASSIGNEE’S
interest in any resulting patent of the United States and countries foreign thereto, and to acquire, hold, enforce, convey, and
uphold the validity of said patent and reissues and extensions thereof, and ASSIGNEE’S interest therein.

ASSIGNOR further agrees to cooperate
with ASSIGNEE in the preparation, drafting, filing, and prosecution of all applications for patent, provisional and nonprovisional,
and foreign counterparts. If ASSIGNEE does not wish to file a particular patent application that claims priority back to Patent
Application Serial No. 13/652,395, they agree to assign the rights back to ASSIGNOR who can pursue a patent application at her
own expense.

ASSIGNOR further agrees to amend
or, if in the determination of the ASSIGNEE an amendment is not feasible, prepare a continuation of Patent Application Serial No.
13/652,395 encompassing the Invention which shall include SiRNA which shall be assigned to ASSIGNEE

SPECIFIC PERFORMANCE

Any breach of this Agreement
may result in irreparable damage to ASSIGNEE for which ASSIGNEE will not have an adequate remedy at law. Accordingly, in addition
to any other remedies and damages available, ASSIGNOR acknowledges and agrees that ASSIGNEE may immediately seek enforcement of
this Agreement by means of specific performance or injunction, without any requirement to post a bond or other security.

EXECUTION

This Agreement may be executed
in two or more counterparts, all of which when taken together shall be considered one and the same Agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not
sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile signature page were an original thereof.

ENTIRE AGREEMENT

This Agreement constitutes a
final written expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete
and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations
between the parties.

SEVERABILITY

If any provision of this Agreement
is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of
this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable
provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this
Agreement

GOVERNING LAW, VENUE, WAIVER
OF JURY TRIAL

All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance
with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of
any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party
shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.

In testimony
whereof ASSIGNOR and ASSIGNEE intending to be legally bound hereunto affixes their signatures below. 

ASSIGNOR

	 	 
	/s/ Christine Ichim	11/20/2014
	Christine Ichim	(Date)

  

ASSIGNEE

	 	 
	/s/ David Koos	11/20/2014
	David Koos	(Date)
	Chairman & CEO	 
	Regen BioPharma, Inc.Exhibit 10.34

 

Consulting
Agreement 

Agreement by and between Christine
Ichim (“Consultant”) , a natural person whose address is at 12685 Campo Road, Spring Valley CA 91978 and Regen Biopharma,
Inc. (“Company”) , a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942.

It is agreed as follows:

1. INVENTIONS

Consultant agrees that she has been specifically
hired by the Company to invent the following:

	 	a)	Cord Blood Small Molecule (“CBSM invention”)

 

	 	b)	Cancer Small Molecule Ligand Binding (“CSMLB Invention”)

 

	 	c)	Cancer Small Molecule Alpha helix Inhibitor (“CSMAI Invention”)

 

	 	d)	Cancer Small Molecule using 170 Compound List (“CSM170 Invention”)

2. PATENT APPLICATIONS

Consultant agrees to file with
the United States Patent and Trademark Office provisional applications for patent and subsequent applications for patent for all
of the CBSM invention, the CSMLB Invention, the CSMAI Invention and the CSM170 Invention

3. ASSIGNMENT

Consultant assigns to the Company 100% of her right,
title, and interest in

	 	i)	CBSM invention

 

	 	ii)	CSMLB Invention

 

	 	iii)	CSMAI Invention

 

	 	iv)	CSM170 Invention

and patent applications filed
for the above (as well as such rights in any divisions, continuations in whole or part or substitute applications) to Company .

Consultant authorizes the United
States Patent and Trademark Office and the equivalent authority of any nation to issue any Patents resulting from applications
for patent for any of the inventions which are the subject of this Agreement to the Company. The right, title and interest is to
be held and enjoyed by the Company and the Company's successors and assigns as fully and exclusively as it would have been held
and enjoyed by Consultant had this assignment not been made..

Consultant further agrees to:
(a) cooperate with Company in the prosecution of all applications for patent, provisional and nonprovisional, and foreign counterparts;
(b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer;
and (c) perform such other acts as Company lawfully may request to obtain or maintain the Patent for the inventions in any and
all countries.

4. CONSIDERATION

	 	v)	As consideration for the invention, patent prosecution and assignment of all right, title and interest to CBSM invention Consultant shall be issued One Hundred Thousand Common Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars to be paid upon the filing with the United States patent and Trademark Office of a provisional applications for patent for the CBSM Invention

 

	 	vi)	As consideration for the invention, patent prosecution and assignment of all right, title and interest to CSMLB invention Consultant shall be issued One Hundred Thousand Common Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars to be paid upon the filing with the United States patent and Trademark Office of a provisional applications for patent for the CSMLB Invention

 

	 	vii)	As consideration for the invention, patent prosecution and assignment of all right, title and interest to CSMAI invention Consultant shall be issued One Hundred Thousand Common Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars to be paid upon the filing with the United States patent and Trademark Office of a provisional applications for patent for the CSMAI Invention

 

	 	viii)	As consideration for the invention, patent prosecution and assignment of all right, title and interest to CSM170 invention Consultant shall be issued One Hundred Thousand Common Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars to be paid upon the filing with the United States patent and Trademark Office of a provisional applications for patent for the CSM170 Invention
	 	v.)	Consultant shall be entitled to royalties during the term of any patent granted for the CBSM invention, CSMLB invention ,CSMAI invention and CSM170 invention of 5% of Net Sales made by the Company of the CBSM invention, CSMLB invention ,CSMAI invention and CSM170 invention. Net Sales" means the monetary consideration actually received by Company for the transfer of the invention less any of the following items

(a) outbound shipping, storage, packing and
insurance expenses;

(b) distributor discounts;

(c) allowance for doubtful accounts or uncollectible
accounts receivable;

(d) amounts repaid or credited as a result
of rejections, defects, or returns

(e) sales and other excise taxes (excluding
VAT), tariffs, export license fees and duties paid to a governmental entity

(f) sales commissions.

5. RESTRICTED
SECURITIES ACKNOWLEDGEMENT

Consultant acknowledges
that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933 shall constitute
“restricted securities” as that term is defined in Rule 144 promulgated under the Securities Act of 1933, and shall
contain the following restrictive legend:

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

6.
SPECIFIC PERFORMANCE

Any breach of this Agreement
may result in irreparable damage to Company for which Company will not have an adequate remedy at law. Accordingly, in addition
to any other remedies and damages available, Consultant acknowledges and agrees that Company may immediately seek enforcement of
this Agreement by means of specific performance or injunction, without any requirement to post a bond or other security.

7. EXECUTION

This Agreement may be executed
in two or more counterparts, all of which when taken together shall be considered one and the same Agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not
sign the same counterpart. In the event that any signature is delivered by facsimile transmission, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile signature page were an original thereof.

8. ENTIRE AGREEMENT

This Agreement constitutes a
final written expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete
and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations
between the parties.

9. SEVERABILITY

If any provision of this Agreement
is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of
this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable
provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this
Agreement.

10. GOVERNING LAW, VENUE,
WAIVER OF JURY TRIAL

All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance
with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of
any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party
shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above. 

Company  

	By:	/s/ David
    R. Koos 
	 	David
    R. Koos
	 	Chairman
    & CEO
	 	Regen
    Biopharma, Inc. 

  

Consultant 

	By:	/s/ Christine Ichim 
	 	Christine
    Ichim, PhD

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]